ETX — E-Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- £54.93m
- £23.53m
- £0.48m
2019 January 31st | 2020 January 31st | 2021 January 31st | R2022 January 31st | 2023 January 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 5.9 | 3.84 | 13 | 26.4 | 31.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.12 | 0.593 | 0.826 | 1.71 | 1.76 |
Prepaid Expenses | |||||
Total Current Assets | 7.35 | 4.58 | 14.1 | 28.6 | 34 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.042 | 0.093 | 0.08 | 0.805 | 0.4 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 7.51 | 4.79 | 14.3 | 29.5 | 34.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.707 | 0.261 | 0.427 | 1.49 | 1.6 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.707 | 0.284 | 0.427 | 1.79 | 1.6 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 6.8 | 4.5 | 13.9 | 27.7 | 33 |
Total Liabilities & Shareholders' Equity | 7.51 | 4.79 | 14.3 | 29.5 | 34.6 |
Total Common Shares Outstanding |